Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2016 Jul 21

PMID 27436274

Citations 31

Affiliations

Soon will be listed here.

Abstract

Objective: The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study has demonstrated the beneficial effect of intensive therapy on atherosclerosis and clinical cardiovascular outcomes, while identifying hyperglycemia as a dominant risk factor for type 1 diabetes. The current analyses evaluate the extent to which glycemic exposure influences long-term changes in established risk factors for cardiovascular disease (CVD) among patients with type 1 diabetes.

Research Design And Methods: The DCCT study randomized 1,441 participants to receive intensive or conventional diabetes therapy; and after an average of 6.5 years of follow-up, 96% of the surviving cohort enrolled in the EDIC observational study for an additional 20 years of follow-up. Annual visits included a detailed medical history and physical examination. Blood and urine samples were collected and assayed centrally. Longitudinal models for repeated measurements were used.

Results: Higher HbA1c level was a significant correlate of the longitudinal changes in all of the traditional CVD risk factors over the 30-year follow-up. The strongest longitudinal associations were among the lipid measurements and concurrent glycemia.

Conclusions: A better understanding of the interrelationships between diabetes-related risk factors and traditional CVD risk factors may assist with the development of targeted treatment regimens for persons with type 1 diabetes who are at risk for CVD.

Citing Articles

A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus.

AlHabeeb W, Elasfar A, Kinsara A, Aljizeeri A, Jelaidan I, Alghalayini K J Saudi Heart Assoc. 2025; 36(4):385-407.

PMID: 39822337 PMC: 11737320. DOI: 10.37616/2212-5043.1407.

Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care.

Caturano A, Galiero R, Rocco M, Tagliaferri G, Piacevole A, Nilo D Biomedicines. 2024; 12(9).

PMID: 39335551 PMC: 11429233. DOI: 10.3390/biomedicines12092039.

The Impact of Metabolic Memory on Immune Profile in Young Patients with Uncomplicated Type 1 Diabetes.

Neubauer-Geryk J, Wielicka M, Mysliwiec M, Zorena K, Bieniaszewski L Int J Mol Sci. 2024; 25(6).

PMID: 38542165 PMC: 10969844. DOI: 10.3390/ijms25063190.

Comprehensive Factors for Predicting the Complications of DiabetesMellitus: A Systematic Review.

Erandathi M, Wang W, Mayo M, Lee C Curr Diabetes Rev. 2024; 20(9):e040124225240.

PMID: 38178670 PMC: 11327746. DOI: 10.2174/0115733998271863231116062601.

Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study.

Bebu I, Braffett B, de Boer I, Aiello L, Bantle J, Lorenzi G Diabetes Care. 2022; 46(2):361-368.

PMID: 36520643 PMC: 9887612. DOI: 10.2337/dc22-1744.

References

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Mahfouz R, Elawady W, Abdu M, Salem A . Associations of fractional pulse pressure to aortic stiffness and their impact on diastolic function and coronary flow reserve in asymptomatic diabetic patients with normal coronary angiography. Cardiol J. 2013; 20(6):605-11. DOI: 10.5603/CJ.2013.0160. View

. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986; 35(5):530-45. View

. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999; 22(1):99-111. PMC: 2745938. DOI: 10.2337/diacare.22.1.99. View

Cleary P, Orchard T, Genuth S, Wong N, Detrano R, Backlund J . The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006; 55(12):3556-65. PMC: 2701297. DOI: 10.2337/db06-0653. View

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View

Ronnback M, Fagerudd J, Forsblom C, Pettersson-Fernholm K, Reunanen A, Groop P . Altered age-related blood pressure pattern in type 1 diabetes. Circulation. 2004; 110(9):1076-82. DOI: 10.1161/01.CIR.0000139903.29522.8D. View

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

Domanski M, Mitchell G, Pfeffer M, Neaton J, Norman J, Svendsen K . Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002; 287(20):2677-83. DOI: 10.1001/jama.287.20.2677. View

10.

de Ferranti S, de Boer I, Fonseca V, Fox C, Golden S, Lavie C . Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014; 37(10):2843-63. PMC: 4170130. DOI: 10.2337/dc14-1720. View

11.

de Boer I, Rue T, Cleary P, Lachin J, Molitch M, Steffes M . Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med. 2011; 171(5):412-20. PMC: 3085024. DOI: 10.1001/archinternmed.2011.16. View

12.

Kaplan N . The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989; 149(7):1514-20. DOI: 10.1001/archinte.149.7.1514. View

13.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

14.

Rasky E, Stronegger W, Freidl W . The relationship between body weight and patterns of smoking in women and men. Int J Epidemiol. 1996; 25(6):1208-12. DOI: 10.1093/ije/25.6.1208. View

15.

. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care. 1992; 15(7):886-94. DOI: 10.2337/diacare.15.7.886. View

16.

Long A, Dagogo-Jack S . Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich). 2011; 13(4):244-51. PMC: 3746062. DOI: 10.1111/j.1751-7176.2011.00434.x. View

17.

Julius S, Valentini M . Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes. Blood Press Suppl. 1999; 3:5-13. DOI: 10.1080/080370598438410-1. View

18.

Kong C, Nimmo L, Elatrozy T, Anyaoku V, Hughes C, Robinson S . Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis. 2001; 156(2):373-8. DOI: 10.1016/s0021-9150(00)00664-x. View

19.

Harjutsalo V, Forsblom C, Groop P . Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ. 2011; 343:d5364. PMC: 3169676. DOI: 10.1136/bmj.d5364. View

20.

Wu L, Parhofer K . Diabetic dyslipidemia. Metabolism. 2014; 63(12):1469-79. DOI: 10.1016/j.metabol.2014.08.010. View